Compare EPAM Systems Inc (EPAM) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs McKesson Corporation — how do they compare? EPAM Systems Inc trades at $113.24 (market cap $5.87B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 18.5× EPAM Systems Inc's market cap, and McKesson Corporation pays a 0.4% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and McKesson Corporation for 74 Days on average.
| EPAM | MCK | |
|---|---|---|
Market Cap | $5.87B | $108.46B |
Volume | 847,420 | 712,607 |
Sector | Technology | Health |
52-Week High | $221.40 | $995.69 |
52-Week Low | $76.04 | $725.17 |
Typical Hold Time | 37 Days | 74 Days |
Enterprise Value | $5.24B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM trades at $113.86, up 5.11% on the day, with a bullish technical signal and strong quarterly earnings beats. Revenue grew to $5.46B in 2025, though net income margin compressed to 6.92%. The company maintains solid profitability with ROE of 11.18% and trades at a P/E of 15.45, below industry averages. Recent news highlights AI-native revenue growth and activist investor pressure for share buybacks.
The outlook is positive with a consensus price target of $119, representing 4.5% upside. Key catalysts include Q3 2026 earnings and AI service expansion, but risks involve North American growth slowdown and competitive pressures in digital transformation services.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
